Trousseau's syndrome treated with long-term subcutaneous lepirudin (case report and review of the literature).
We report here a case of recurrent venous and arterial thromboembolism, Trousseau's syndrome, in a cancer patient who developed heparin-induced thrombocytopenia. She was treated with lepirudin and after establishing the patient-specific half-life for subcutaneous lepirudin, she was successfully maintained on this therapy for more than eight months. To our knowledge this case represents the longest reported use of subcutaneous lepirudin.
Andreescu
A C
AC
Department of Medicine, University of Vermont, Burlington 05401, USA.
Cushman
M
M
Hammond
J M
JM
Wood
M E
ME
D000925:Anticoagulants / Q000008:administration & dosage; D001157:Arterial Occlusive Diseases / Q000188:drug therapy / Q000209:etiology; D005260:Female; D006493:Heparin / Q000009:adverse effects; D006629:Hirudins / Q000008:administration & dosage* / Q000031:analogs & derivatives; D006801:Humans; D007279:Injections, Subcutaneous; D007700:Kinetics; D008875:Middle Aged; D010257:Paraneoplastic Syndromes / Q000188:drug therapy*; D010314:Partial Thromboplastin Time; D011994:Recombinant Proteins / Q000008:administration & dosage*; D012008:Recurrence; D013921:Thrombocytopenia / Q000139:chemically induced; D013923:Thromboembolism / Q000188:drug therapy / Q000209:etiology; D020246:Venous Thrombosis / Q000188:drug therapy / Q000209:etiology
D000925:Anticoagulants; D006629:Hirudins; D011994:Recombinant Proteins; D006493:Heparin; C083544:lepirudin